NCT04778826 is a NA clinical trial of Lymphadenectomy in Lung Neoplasm Malignant, sponsored by Otto Wagner Hospital.

Who is sponsoring NCT04778826?

NCT04778826 is sponsored by Otto Wagner Hospital.

What drugs are being tested in NCT04778826?

Interventions in NCT04778826: Lymphadenectomy.

What condition does NCT04778826 study?

NCT04778826 studies Lung Neoplasm Malignant.

Is NCT04778826 still recruiting?

NCT04778826 is currently status unknown. Last updated 3 March 2021.

Last reviewed 2021-03-03 · How we verify

NCT04778826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy

Status unknown NA Last updated 3 March 2021

What this trial tests

NA trial testing Lymphadenectomy in Lung Neoplasm Malignant in 200 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
31 December 2022

1 March 2023

Quick facts

Lead sponsor	Otto Wagner Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	200
Start date	1 October 2020
Primary completion	31 December 2022
Estimated completion	1 March 2023
Sites	1 location across Austria

Drugs / interventions tested

Lymphadenectomy

Conditions studied

Lung Neoplasm Malignant — all drugs for Lung Neoplasm Malignant →

Sponsor

Otto Wagner Hospital

Who can join

18 and older, any sex, with Lung Neoplasm Malignant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Any kind of anatomical lung resection for lung cancer with curative intent has to be accompanied by formal mediastinal lymph node dissection. Video-assisted mediastinoscopic lymphadenectomy through a cervical access (VAMLA) along with thoracoscopic lobectomies in the same setting offers improved radicality through bilateral mediastinal dissection, provide accurate staging, does not require single lung ventilation and hence ideally supports the concept of minimally invasive surgery. Due to the VAMLA associated radicality, the investigator believes that using of VAMLA along with lobectomy could improve the oncological outcome of lung cancer patients. Furthermore, the absence of single lung ventilation during VAMLA could attenuate the surgically induced immunosuppression.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Enhanced recovery in lung surgery: coaxial versus conventional chest drains following video-assisted thoracoscopic surgery lobectomy-a prospective randomized trial.
Salama M, Mueller MR. · · 2025 · PMID 41376917 · DOI 10.21037/jtd-2025-1169

Verify or expand the search:

Other trials of Lymphadenectomy

Trials testing the same drug.

NCT07139951 — Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and G · Phase 2 · enrolling by invitation
NCT06990737 — Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk · Phase 2 · recruiting
NCT05836584 — Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophagea · Phase 2 · active not recruiting
NCT05581589 — Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT05048173 — Sentinel Lymph Node Biopsy Versus Lymphadenectomy in Endometrial Cancer · completed

Other recruiting trials for Lung Neoplasm Malignant

Currently open trials in the same condition.

NCT07286149 — A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) · Phase 1, PHASE2 · recruiting
NCT07071103 — Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors · Phase 2 · recruiting
NCT06788912 — Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAK · Phase 2 · recruiting
NCT06440616 — Benefit of Spectral Information in Patients Suspected for Lung Cancer · NA · recruiting
NCT06079970 — Confocal Laser Endomicroscopy VERification · NA · recruiting

Other Otto Wagner Hospital trials

Trials by the same sponsor.

NCT03204968 — The Effect of Vagus Nerve Stimulation on the Inflammatory Response After Lung Lobectomy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04778826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Otto Wagner Hospital
Last refreshed: 3 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04778826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing